Antipsoriatic anthrones: Aspects of oxygen radical formation, challenges and prospects

General Pharmacology

Volumn 27, Issue 8, 1996, Pages 1325-1335

  Müller, Klaus ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

anthralin; anthrones; antiproliferative action; dithranol; free radicals; lipoxygenase inhibition; psoriasis; reactive oxygen species; skin inflammation

Indexed keywords

ANTHRONE; ANTIPSORIASIS AGENT; BUTANTRONE; CHRYSAROBIN; DITHRANOL; FREE RADICAL; LIPOXYGENASE INHIBITOR; LONAPALENE; OXYGEN RADICAL; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

AUTOOXIDATION; CELL PROLIFERATION; DRUG MECHANISM; HUMAN; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; REVIEW; SKIN INFLAMMATION;

ADMINISTRATION, TOPICAL; ANTHRALIN; ANTI-INFLAMMATORY AGENTS; DERMATITIS; DNA DAMAGE; ENZYME INHIBITORS; FREE RADICALS; HUMANS; LIPID PEROXIDATION; OXYGEN CONSUMPTION; PSORIASIS; REACTIVE OXYGEN SPECIES;

EID: 0030561240     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(96)00075-4     Document Type: Review

References (101)

1. Anderson R. (1989) Dithranol-mediated, dose-dependent priming and activation of luminol-enhanced chemiluminescence response of human neutrophils in vitro. Br. J. Dermatol. 121, 1-9.
2. Aruoma O. I., Halliwell B. and Dizdaroglu M. (1989a) Iron ion-dependent modification of bases in DNA by the superoxide radical-generating system hypoxanthine/xanthine oxidase. J. Biol. Chem. 264, 13024-13028.
3. Aruoma O. I., Halliwell B., Gajewski E. and Dizdaroglu M. (1989b) Damage to the bases in DNA induced by hydrogen peroxide and ferric ion chelates. J. Biol. Chem. 264, 20509-20512.
4. Ashton R. E., Andre P., Lowe N. J. and Whitefield M. (1983) Anthralin: historical and current perspectives. J. Am. Acad. Dermatol. 9, 173-192.
5. Bartel R. L., Marcelo C. L. and Voorhees J. J. (1987) Partial characterization of phospholipase C activity in normal, psoriatic uninvolved, and lesional epidermis. J. Invest. Dermatol. 88, 447-451.
6. Battalora M. S. J., Kruszewski F. H. and DiGiovanni J. (1993) Inhibition of chrysarobin skin tumor promotion in SENCAR mice by antioxidants. Carcinogenesis 14, 2507-2512.
7. Bedord C. J., Young J. M. and Wagner B. M. (1983) Anthralin inhibition of mouse epidermal arachidonic acid lipoxygenase in vitro. J. Invest. Dermatol. 81, 566-571.
8. 2 in tissue homogenates and its application to human skin. Biochim. Biophys. Acta 876, 327-332.
9. Bindoli A. (1988) Lipid peroxidation in mitochondria. Free Radical Biol. Med. 5, 247-261.
10. Birnboim H. C. (1986) DNA strand breaks in human leukocytes induced by superoxide anion, hydrogen peroxide and tumor promoters are repaired slowly compared to breaks induced by ionizing radiation. Carcinogenesis 7, 1511-1517.
11. Black H. S. (1989) Role of reactive oxygen species in inflammatory process. In: Nonsteroidal anti-inflammatory drugs. Pharmacology and the skin Vol. 2 (Edited by Hensby C. and Lowe N. J.) S. Karger, Basel, pp. 1-20.
12. Breen A. P. and Murphy J. A. (1995) Reactions of oxyl radicals with DNA. Free Radical Biol. Med. 18, 1033-1077.
13. Bruce J. M., Dodd N. F. J., Gorman A. A., Hamblett I., Kerr C. W., Lambert C. and McNeeney S. P. (1990) Anthralin-derived transients - II. Formation of the radical by spontaneous fragmentation of both singlet and triplet states of the 10,10′-dehydrodimer: radical pair multiplicity effects. Photochem. Photobiol. 52, 345-352.
14. Bruce J. M., Kerr C. W. and Dodd N. J. F. (1987) Formation of superoxide during the auto-oxidation of anthralin (1,8-dihydroxy-9-anthrone). J. Chem. Soc., Faraday Trans. I 83, 85-89.
15. Burdon R. H. (1995) Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radical Biol. Med. 18, 775-794.
16. Cavey D., Caron J.-C. and Shroot B. (1982) Anthralin: chemical instability and glucose-6-phosphate dehydrogenase inhibition. J. Pharm. Sci. 71, 980-983.
17. Clark J. M. and Hanawalt P. C. (1982) Inhibition of DNA replication and repair by anthralin or danthron in cultured human cells. J. Infest. Dermatol. 79, 18-22.
18. Dabestani R., Hall R. D., Sik R. H. and Chignell C. F. (1990) Spectroscopic studies of cutaneous photosensitizing agents - XV. Anthralin and its oxidation product 1,8-dihydroxyanthraquinone. Photochem. Photobiol. 52, 961-971.
19. Davies A. G., Hawari J. A.-A. and Whitefteld M. (1983) Generation and ESR spectrum of the 1,8-dihydroxy-9-anthrone-10-yl-radical. Tetrahedron Lett. 24, 4465-4468.
20. Davies K. J. A., Delsignore M. E. and Lin S. W. (1987) Protein damage and degradation by oxygen radicals. II. Modification of amino acids. J. Biol. Chem. 262, 9902-9907.
21. Dogan P., Soyuer Ü. and Tanrikulu G. (1989) Superoxide dismutase and myeloperoxidase activity in polymorphonuclear leukocytes, and serum ceruloplasmin and copper levels, in psoriasis. Br. J. Dermatol. 120, 239-244.
22. Finnen M. J., Lawrence C. M. and Shuster S. (1984) Inhibition of dithranol inflammation by free-radical scavengers. Lancet 2, 1129-1130.
23. Forrester D. M. T., Van Rensburg C. E. J. and Anderson R. (1991) Pro-oxidative interactions of dithranol with human phagocytes promote oxidative damage to DNA of bystander leukocyte. Mutat. Res. 247, 39-44.
24. Fry L. (1988) Psoriasis. Br. J. Dermatol. 119, 445-461.
25. Fuchs J. and Milbradt R. (1994) Antioxidant inhibition of skin inflammation induced by reactive oxidants: evaluation of the redox couple dihydrolipoate/lipoate. Skin Pharmacol. 7, 278-284.
26. Fuchs J., Milbradt R. and Zimmer G. (1990a) Multifunctional analysis of the interaction of anthralin and its metabolites anthraquinone and anthralin dimer with the inner mitochondrial membrane. Arch. Dermatol. Res. 282, 47-55.
27. Fuchs J., Nitschmann W. H. and Packer L. (1990b) The antipsoriatic compound anthralin influences bioenergetic parameters and redox properties of energy transducing membranes. J. Invest. Dermatol. 94, 71-76.
28. Fuchs J. and Packer L. (1989) Investigations on anthralin free radicals in model systems and in skin of hairless mice. J. Invest. Dermatol. 92, 677-682.
29. Girotti A. W. (1990) Photodynamic lipid peroxidation in biological systems. Photochem. Photobiol. 51, 497-509.
30. Gutteridge J. M. C. (1993) Free radicals in disease processes: a compilation of cause and consequence. Free Radical Res. Commun. 19, 141-158.
31. Halliwell B. (1990) How to characterize a biological antioxidant. Free Radical Res. Commun. 9, 1-32.
32. Halliwell B. and Aruoma O. I. (1991) DNA damage by oxygen-derived species. Its mechanism and measurement in mammalian systems. FEBS Lett. 281, 9-19.
33. Halliwell B. and Gutteridge J. M. C. (1989) Free Radicals in Biology and Medicine, 2nd Ed. Clarendon Press, Oxford.
34. Halliwell B. and Gutteridge J. M. C. (1990) Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol. 186, 1-85.
35. Halmekoski J., Vilvala R. and Mustakallio K. K. (1982) Polarographic studies on dithranol and its 10-acyl analogs. In: Psoriasis (Edited by Farber E. M., Cox A. J., Nall L. and Jacobs P. H.) Grime & Stratton, New York, pp. 381-382.
36. Hayden P. J. and Chignell C. F. (1993) Detection and characterization of 9-anthron-10-yl radicals formed by antipsoriatic and tumor-promoting 9-anthrones in aqueous buffers. Chem. Res. Toxicol. 6, 231-237.
37. Hayden P. J., Free K. E. and Chignell C. F. (1994) Structure-activity relationships for the formation of secondary radicals and inhibition of keratinocyte proliferation by 9-anthrones. Mol. Phormacol. 46, 186-198.
38. Hellier F. F. and Whitefield M. (1967) The treatment of psoriasis with triacetoxyanthracene. Br. J. Dermatol. 79, 491-496.
39. Hsieh G. C. and Acosta D. (1991) Dithranol-induced cytotoxicity in primary cultures of rat epidermal keratinocytes. I. The role of reactive oxygen species. Toxicol. Appl. Pharmacol. 107, 16-26.
40. Ippen H. (1981) Basic questions on toxicology and pharmacology of anthralin. Br. J. Dermatol. 105, (Suppl. 20) 72-76.
41. Kasai H. and Nishimura S. (1991) Formation of 8-hydroxydeoxyguanosine in DNA by oxygen radicals and its biological significance. In: Oxidative stress. Oxidants and antioxidants. (Edited by Sies H.) Academic Press, London, pp. 99-116.
42. Kemény E., Csato M. and Dobozy A. (1989) Pharmacological studies on dithranol-induced irritative dermatitis in mice. Arch. Dermatol. Res. 281, 362-365.
43. Kemény L., Ruzicka T. and Braun-Falco O. (1990) Dithranol: a review of the mechanism of action in the treatment of psoriasis vulgaris. Skin Pharmacol. 3, 1-20.
44. Kobayashi T., Matsumoto M., Iizuka H. and Taniguchi N. (1991) Superoxide dismutase in psoriasis, squamous cell carcinoma and basal cell epithelioma: an immunohistochemical study. Br. J. Dermatol. 124, 555-559.
45. Kobza Black A., Camp R. D. R., Mallet A. I., Cunningham F. M., Hofbauer M. and Greaves M. W. (1990) Pharmacologic and clinical effect of lonapalene (RS 43179), a 5-lipoxygenase inhibitor, in psoriasis. J. Invest. Dermatol. 95, 50-54.
46. Kohen E., Kohen C., Morlière P., Santus R., Reyftmann J. P., Dubertret L., Hirschberg J. G. and Coulomb B. (1986) A microspectrofluorometric study of the effect of anthralin, an antipsoriatic drug, on cellular structures and metabolism. Cell. Biochem. Funct. 4, 157-168.
47. -, and reducing free radicals in causing damage to biomembranes. A study of radiation damage to erythrocyte ghosts using selective free radical scavengers. Biochim. Biophys. Acta 640, 313-325.
48. 4 stimulate DNA synthesis in cultured human epidermal keratinocytes. Br. J. Dermotol. 113, 43-52.
49. Krebs A. and Schaltegger H. (1965) Untersuchungen zum Wirkungsmechanismus von Chrysarobin und Dithranol (= Cignolin) bei Psoriasis. Hinweise für eine cytostatische Wirkung dieser Medikamente. Experientia 21, 128-129.
50. Krebs A., Schaltegger H. and Schaltegger A. (1981) Structure specificity of the antipsoriatic anthrones. Br. J. Dermatol. 105, (Suppl. 20) 6-11.
51. Lambelet P., Ducret F., Löliger J., Maignan J., Reichert U. and Shroot B. (1990) The relevance of secondary radicals in the mode of action of anthralin. Free Radical Biol. Med. 9, 183-190.
52. Lambelet P., Löliger J. and Shroot B. (1988) Role of free radicals in the mode of action of anthralin. Skin Pharmacol. 1, 115-121.
53. Lawrence C. M., Shuster S., Collins M. and Bruce J. M. (1987) Reduction of anthralin inflammation by potassium hydroxide and teepol. Br. J. Dermatol. 116, 171-177.
54. Martinmaa J., Juselius J. and Mustakallio K. K. (1981) Free radicals by auto-oxidation of anthralin and its 10-acyl analogues. Br. J. Dermatol. 105, (Suppl. 20) 52.
55. Martinmaa J., Vanhala L. and Mustakallio K. K. (1978) Free radical intermediates produced by autoxidation of 1,8-dihydroxy-9-anthrone (dithranol) in pyridine. Experientia 34, 872-873.
56. Miller D. M., Buettner G. R. and Aust S. D. (1990) Transition metals as catalysts of "autoxidation" reactions. Free Radical Biol. Med. 8, 95-108.
57. Motten A. G., Sik R. H., Chignell C. F. and Hayden P. J. (1994) An EPR study of free radicals formed by antipsoriatic and tumor-promoting 9-anthrones in nonpolar solvents. Chem. Res. Toxicol. 7, 877-881.
58. Mrowietz U., Falsafi M., Schröder J.-M. and Christophers E. (1992) Inhibition of human monocyte functions by anthralin. Br. J. Dermatol. 127, 382-386.
59. Müller K. (1988) Active oxygen species and structure specificity of antipsoriatic anthrones. Arch. Pharm. (Weinheim, Ger.) 321, 385-389.
60. Müller K. (1994) 5-Lipoxygenase and 12-lipoxygenase: attractive targets for the development of novel antipsoriatic drugs. Arch. Pharm. (Weinheim, Ger.) 327, 3-19.
61. Müller K., Eibler E., Mayer K. K., Wiegrebe W. and Klug G. (1986a) Dithranol, singlet oxygen and unsaturated fatty acids. Arch. Pharm. (Weinheim, Ger.) 319, 2-9.
62. Müller K. and Gawlik I. (1995) Novel 10-substituted antipsoriatic anthrones as inhibitors of epidermal 12-lipoxygenase and lipid peroxidation in membranes. Biochem. Pharmacol. 50, 2077-2083.
63. Müller K. and Gawlik I. (1996) Inactivation of mouse epidermal 12-lipoxygenase by anthralin - implications for a role of oxygen radicals. Biochem. Pharmacol. 51, 1173-1179.
64. Müller K. and Gürster D. (1993) Hydroxyl radical damage to DNA sugar and model membranes induced by anthralin (dithranol). Biochem. Pharmacol. 46, 1695-1704.
65. Müller K., Gürster D., Piwek S. and Wiegrebe W. (1993) Antipsoriatic anthrones with modulated redox properties. 1. Novel 10-substituted 1,8-dihydroxy-9(10H)-anthracenones as inhibitors of 5-lipoxygenase. J. Med. Chem. 36, 4099-4107.
66. Müller K., Kanner R. C. and Foote C. S. (1990) Kinetic studies on anthralin photooxidation. Photochem. Photobiol. 52, 445-450.
67. Müller K. and Kappus H. (1988) Hydroxyl radical formation by dithranol. Biochem. Pharmacol. 37, 4277-4280.
68. Müller K., Leukel P., Mayer K. K. and Wiegrebe W. (1995) Modification of DNA bases by anthralin and related compounds. Biochem. Pharmacol. 49, 1607-1613.
69. Müller K., Leukel P., Ziereis K. and Gawlik I. (1994) Antipsoriatic anthrones with modulated redox properties. 2. Novel derivatives of chrysarobin and isochrysarobin - antiproliferative activity and 5-lipoxygenase inhibition. J. Med. Chem. 37, 1660-1669.
70. 2-Oxidation of dithranol to chrysazin. Arch. Pharm. (Weinheim, Ger.) 319, 1009-1018.
71. Müller K., Seidel M., Braun C., Ziereis K. and Wiegrehe W. (1991) Dithranol, glucose-6-phosphate dehydrogenase inhibition and active oxygen species. Arzneim.-Forsch. 41, 1176-1181.
72. Müller K., Wiegrebe W. and Younes M. (1987) Formation of active oxygen species hy dithranol, III. Dithranol, active oxygen species and lipid peroxidation in vivo. Arch. Pharm. (Weinheim, Ger.) 320, 59-66.
73. Musser J. H. and Kreft A. F. (1992) 5-Lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors. J. Med. Chem. 35, 2501-2524.
74. Mustakallio K. K. (1988) Anthralin and related compounds. Past, present and future. In: Psoriasis, Proceedings of the Fourth International Symposium (Edited hy Farber E. M., Nall L., Morhenn V. and Jacobs P. H.) Elsevier, New York, pp. 172-180.
75. Mustakallio K. K. (1992) The history of dithranol and related hydroxyanthrones, their efficacy, side effects, and different regimens employed in the treatment of psoriasis. Acta Derm.-Venereol. (Stockholm), Suppl. 172, 7-9.
76. Mustakallio K. K. and Brandt H. ( 1981 ) Irritation, staining and antipsoriatic activity of some 10-acyl analogues of anthralin. Br. J. Dermatol. (Suppl. 20) 105, 51.
77. Opas E. E., Argenbright L. W. and Humes J. L. (1989) An enzymatic method for distinguishing the stereoisoniers ot 12-hydroxyeicosatetraenoic acid in human epidermis and psoriatic scale. Br. J. Dermatol. 120, 49-58.
78. Paramsothy Y. and Lawrence C. M. (1987) Time course and intensity of anthralin inflammation on involved and uninvolved psoriatic skin. Br. J. Dermatol. 116, 517-519.
79. Pečar S., Schara M., Müller K. and Wiegrebe W. (1995) Reduction of nitroxides by anthralin and some of its derivatives. Free Radical Biol. Med. 18, 459-465.
80. Raab W. P. (1981) Ingram method: the precursor of photochemotherapy. Br. J. Dermatol. 105, (Suppl. 20) 77-81.
81. Reichert U., Jacques Y., Grangeret M. and Schmidt R. (1985) Antirespiratory and antiproliferative activity of anthralin in cultured human keratinocytes. J. Invest. Dermatol. 84, 130-134.
82. Ruzicka T. (1990) Eicosanoids in psoriasis. J. Dermatol. Sci. 1, 415-424.
83. Ruzicka T. and Printz M. P. (1984) Arachidonic acid metabolism in skin: a review. Rev. Physiol. Biochem. Pharmacol. 100, 121-160.
84. Sa e Melo T., Dubertret L., Prognon P., Gond A., Mahuzier G. and Santus R. (1983) Physicochemical properties and stability of anthralin in model systems and human skin. J. Invest. Dermatol. 80, 1-6.
85. Schallreuter K. U. and Pittelkow M. R. (1987) Anthralin inhibits elevated levels of thioredoxin reductase in psoriasis. Arch. Dermatol. 123, 1494-1498.
86. Schallreuter K. U. and Wood J. M. (1989) Free radical reduction in the human epidermis. Free Radical Biol. Med. 6, 519-532.
87. 4-ω oxidation by human neutrophils. J. Invest. Dermatol. 87, 624-629.
88. Schröder J. M., Kosfeld U. and Christophers E. (1985) Multifunctional inhibition by anthralin in nonstimulated and chemotactic factor stimulated human neutrophils. J. Invest. Dermatol. 85, 30-34.
89. Shroot B. (1992) Mode of action of dithranol, pharmacokinetics/dynamics. Acta Derm.-Venereol. (Stockholm), Suppl. 172, 10-12.
90. Shroot B. and Brown C. (1986) Free radicals in skin exposed to dithranol and its derivatives. Arzneim.-Forsch. 36, 1253-1255.
91. Sies H. (1986) Biochemistry of oxidative stress. Angew. Chem. Int. Ed. Engl. 25, 1058-1071.
92. Stadtman E. R. (1990) Metal ion-catalyzed oxidation of proteins: biochemical mechanism and biological consequences. Free Radical Biol. Med. 9, 315-325.
93. Trenam C. W., Blake D. R. and Morris C. J. (1992) Skin inflammation: reactive oxygen species and the role of iron. J. Invest. Dermatol. 99, 675-682.
94. Trush M. A., Mimnaugh E. G. and Gram T. E. (1982) Activation of pharmacological agents to radical intermediates. Implications for the role of free radicals in drug action and toxicity. Biochem. Pharmacol. 31, 3335-3346.
95. van de Kerkhof P. M. C. (1991) Dithranol treatment for psoriasis: after 75 years, still going strong! Eur. J. Dermatol. 1, 79-88.
96. Viluksela M. (1991) Characteristics and modulation of dithranol (anthralin)-induced skin irritation in the mouse ear model. Arch. Dermatol. Res. 283, 262-268.
97. Ward P. A., Warren J. S. and Johnson K. J. (1988) Oxygen radicals, inflammation, and tissue injury. Free Radical Biol. Med. 5, 403-408.
98. Wiegrebe W. and Müller K. (1995) Treatment of psoriasis with anthtones -chemical principles, biochemical aspects, and approaches to the design of novel derivatives. Skin Pharmacol. 8, 1-24.
99. Winyard P. G., Morris C. J., Winrow V. R., Zaidi M. and Blake D. R. (1994) Free radical pathways in the inflammatory response. New Compr. Biochem. 28, 361-383.
100. Yamamoto S. (1991) "Enzymatic" lipid peroxidation: reactions of mammalian lipoxygenases. Free Radical Biol. Med. 10, 149-159.
101. Ziboh V. A. (1988) Psoriasis: Hyperproliferative/inflammatory skin disorder. Drug Dev. Res. 13, 137-146.